Pain medicine (Malden, Mass.) · 2025
Effectiveness of platelet-rich plasma for treating temporomandibular joint disorders: a systematic review and meta-analysis of randomized controlled trials.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tsai Jui-Hsu, Tam Ka-Wai, Yang Jheng-Dao, Hsu Tzu-Herng
Аннотация
OBJECTIVE: To investigate the therapeutic effects of platelet-rich plasma (PRP) injection on pain and mandibular movement in patients with temporomandibular joint disorder (TMJD).
DESIGN: Systematic review and meta-analysis of prospective controlled trials. A literature search was conducted in PubMed, Embase, and the Cochrane Library to identify relevant studies published before August 31, 2024.
SETTING: Not applicable (systematic review and meta-analysis).
PARTICIPANTS: Patients diagnosed with temporomandibular joint disorder included in the eligible studies.
INTERVENTION(S) OR EXPOSURE(S): PRP injection compared with arthrocentesis, hyaluronic acid, or corticosteroids.
MAIN OUTCOME(S) AND MEASURE(S): Pain intensity and maximal mandibular opening (MMO) were the primary outcomes. Study quality was assessed using the Cochrane Risk of Bias 2.0 tool for randomized trials and ROBINS-I for nonrandomized studies. Mean difference (MD) or standardized MD with 95% confidence intervals (CIs) was used to evaluate effect size.
RESULTS: This meta-analysis included 31 studies involving 1359 patients. Compared to arthrocentesis, PRP significantly reduced pain at 6 months (MD, -1.56; 95% CI, -2.68 to -0.44) and improved mandibular movement at 3 months (MD, 2.16; 95% CI, 0.30 to 4.02) and 6 months (MD, 2.56; 95% CI, 0.76 to 4.35). Compared to hyaluronic acid, PRP significantly reduced pain at 3 months (MD, -2.18; 95% CI, -3.70 to -0.66) and improved mandibular movement at 6 months (MD, 3.67; 95% CI, 1.26 to 6.07). Compared to corticosteroids, PRP reduced pain at 1 month (MD, -0.41; 95% CI, -0.81 to -0.02), 3 months (MD, -2.18; 95% CI, -3.70 to -0.66), and 6 months (MD, -1.25; 95% CI, -1.52 to -0.97), and improved mandibular movement at 6 months (MD, 1.46; 95% CI, 0.27 to 2.64).
CONCLUSIONS AND RELEVANCE: PRP injection may be an effective and safe treatment for patients with TMJD. These findings suggest that PRP could serve as a promising minimally invasive option for improving pain and mandibular function in clinical settings.
DESIGN: Systematic review and meta-analysis of prospective controlled trials. A literature search was conducted in PubMed, Embase, and the Cochrane Library to identify relevant studies published before August 31, 2024.
SETTING: Not applicable (systematic review and meta-analysis).
PARTICIPANTS: Patients diagnosed with temporomandibular joint disorder included in the eligible studies.
INTERVENTION(S) OR EXPOSURE(S): PRP injection compared with arthrocentesis, hyaluronic acid, or corticosteroids.
MAIN OUTCOME(S) AND MEASURE(S): Pain intensity and maximal mandibular opening (MMO) were the primary outcomes. Study quality was assessed using the Cochrane Risk of Bias 2.0 tool for randomized trials and ROBINS-I for nonrandomized studies. Mean difference (MD) or standardized MD with 95% confidence intervals (CIs) was used to evaluate effect size.
RESULTS: This meta-analysis included 31 studies involving 1359 patients. Compared to arthrocentesis, PRP significantly reduced pain at 6 months (MD, -1.56; 95% CI, -2.68 to -0.44) and improved mandibular movement at 3 months (MD, 2.16; 95% CI, 0.30 to 4.02) and 6 months (MD, 2.56; 95% CI, 0.76 to 4.35). Compared to hyaluronic acid, PRP significantly reduced pain at 3 months (MD, -2.18; 95% CI, -3.70 to -0.66) and improved mandibular movement at 6 months (MD, 3.67; 95% CI, 1.26 to 6.07). Compared to corticosteroids, PRP reduced pain at 1 month (MD, -0.41; 95% CI, -0.81 to -0.02), 3 months (MD, -2.18; 95% CI, -3.70 to -0.66), and 6 months (MD, -1.25; 95% CI, -1.52 to -0.97), and improved mandibular movement at 6 months (MD, 1.46; 95% CI, 0.27 to 2.64).
CONCLUSIONS AND RELEVANCE: PRP injection may be an effective and safe treatment for patients with TMJD. These findings suggest that PRP could serve as a promising minimally invasive option for improving pain and mandibular function in clinical settings.